IP Library › Granted Patent US 9,187,430
Granted Patent B2
US 9,187,430 · App. 14/361,698 · Granted Nov 17, 2015

Poly (ADP-ribose) polymerase inhibitor

Inventors: Jianxin Ji (Chengdu, CN); Na Guo (Chengdu, CN); Ting Xue (Chengdu, CN); Bingqiang Kang (Chengdu, CN); Xinfa Ye (Chengdu, CN); Xin Chen (Chengdu, CN); Tao Zhang (Chengdu, CN)
Assignee: CHENGDU DI'AO PHARMACEUTICAL GROUP CO., LTD.
C07D237/32A61K31/502A61K31/5025C07D401/12C07D401/14C07D407/14C07D409/14C07D413/14C07D417/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,187,430
App. No.
14/361,698
Granted
Nov 17, 2015
Kind
B2
Abstract

Disclosed are a phthalic hydrazide (phthalazine ketone) compound, and a pharmaceutical composition comprising the same. As a DNA repair enzyme poly (ADP-ribozyme) polymerase inhibitor, the compound and the pharmaceutical composition can effectively treat diseases involving PARP enzymatic activity, including cancer, neural degenerative diseases, inflammation and the like.

Claims (2)

1. The compound 4-(3-(4-(1-(dimethylamino)cyclopropanecarbonyl) piperazine-1-carbonyl)-4-fluorophenoxy)2H-phthalazin-1-one, pharmaceutically acceptable salt or stereoisomer thereof.

2. A pharmaceutical composition comprising an effective amount of the compound, pharmaceutically acceptable salt or stereoisomer thereof, of claim 1 , and a pharmaceutically acceptable carrier.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 29, 2014
From: JI, JIANXIN; GUO, NA; XUE, TING; KANG, BINGQIANG; YE, XINFA; CHEN, XIN; ZHANG, TAO
To: CHENGDU DI'AO PHARMACEUTICAL GROUP CO., LTD.
Reel/Frame 032992/0334 →
Priority Claims (1)
CN 2011 1 0390364 · Nov 30, 2011 · national
Continuity (1)
Related Publication 20150051211A1 · Feb 19, 2015